Tip 2 diabetik hastalarda lipoprotein a , plazma kolinesteraz ve diğer risk faktörleri

Year 2000, Volume: 6 Issue: 1-2 - 2000, 1 - 4, 18.06.2000

M. Ramazan Şekeroğlu Selim Topal Ekrem Algün Mehmet Tarakçıoğlu Haluk Dülger

Abstract

Serum Lipoprotein a [Lp a ] konsantrasyonu ateroskleroz için bağımsız bir risk faktörü olarak kabul edilmektedir. Ateroskleroz da diabetik hastalarda ölümün en yaygın sebebidir. Bu çalışma 30 sağlıklı kontrol ortalama yaş: 49.7 yıl ile glisemik kontrol altında olan 30 tip 2 diabetes mellituslu hastada ortalama yaş:51.9 yıl gerçekleştirildi. Her iki grupta da Lp a , glukoz, total kolesterol, HDL-kolesterol. LDL-kolesterol, trigliserid, Apo Al, Apo B ve HbAlC seviyeleri ile kolinesteraz aktivitesi saptandı. Diabetik grupta kolinesteraz. apo B, trigliserid, glukoz ve HbAlC seviyeleri kontrol grubundan yüksekti p

Keywords

Diabetes mellitus, Lp(a), kolinesteraz

Lipoprotein a , plasma cholinesterase and other risk factors in patients with type 2 diabetes mellitus

Abstract

The serum Lipoprotein a [Lp a J concentration is an independent risk factor for atherosclerosis. Atherosclerosis is the most common cause of death in diabetic patients. Thirty patients with type 2 diabetes mellitus age: range 40-63 years; mean 51.9 years , and 30 healthy Controls age: range 40-58 years; mean 49.7 years participated in this study. The levels of Lp a , glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, apo A, apo B. HbAıc and cholinesterase activity in both groups were determined. Cholinesterase. apo B. triglyceride, glucose and Hb Aıc values of diabetic group were higher than those of the control group p

Keywords

Diabetes mellitus, Lp(a), cholinesterase

References

• Türkmen F, Akkuş İ, Büyükbaş S, Çığlı A: Diyabetes mellitusta biyokimyasal değişiklikler ve komplikasyonlar. T Klin Tıp Bilimleri 10(1): 1-10, (1990).
• Dunn FL. Hiperlipidemia and diabetes. Med Clin North Am 66(6): 1347- 1360, (1982).
• Gaııbatz JW, Heideman C, Gotto AM, Moırisett JD, Dahlen GH: Isolation and characteıisation of the two majör apoproteins in human lipoprotein (a). J Biol Chem 258: 4582-4589, (1983).
• Mc Clean JA, Tomlihson J, Kuang WJ, Eaton D, Chen E, Flees G, Scanu A, Lawn R: DNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330: 132-137, (1987).
• Hajjar AA, Gawish D, Breslow JL. Nachman RL: Lipoprotein (a) modıılation of endothelial celi surface fıbrinolysis and its potential role in atherosclerosis. Nature 39: 303-330. (1989).
• Uterman G: Lipoprotein (a) : a genetic risk factor for prematüre coronary heart disease. Curr Opin Lipidol 1: 404-410, (1989).
• Koster GM, Avogaro P, Cazzolato G, Maıth E, Bittolo-Bon G, Qunici GB: Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis 38:51-61,(1981).
• Guillausseau PJ, Peynet J. Chanson P, Legıand A, Altmann JJ, Poupon JN, Guyen M, Rousselet F: Lipoprotein (a) in diabetic patients with and without chronic renal failure. Diabetes Çare 15(8): 976-979, (1992).
• Bıucket E, Davidooff P, Grimaldi A, Truffert G, Giıal P, Doumitou R. Teı vet F, Degennes JI: Increased serum levels of lipoprotein (a) in diabetes mellitus and their reduction with glicemic control. J Am Med Assoc 263: 35-36, (1990).
• Ritter M.M, Coscar M, Richter US, Schwandt P: Lipoprotein (a) in diabetes mellitus. Clin Chim Açta 214: 45-54, (1993).
• Haffner SM, Morales, PA, S tem MP, Gıuber MK: Lp (a) concentıations in NIDDM Diabetes 41: 1267-1272,(1992).
• Taupin JM, Durlach V, Hassaim M, Giller P, Jolly D, Boirie Y, Grulet H, Leutenegger M: Lipoprotein (a) and diabetes, relationship based on 224 cases. Diabet Metab 19(2): 250-256, (1993).
• Kostner GM: Standardization of Lp (a) Assay (letter). Clin Chim Açta 21 1: 191 -194, (1992).
• Kutty KM. Jain R. Huang SN: Serum pseudo-cholinesterase; High densty lipoprotein cholesteıol as an index of risk for caıdiovascular disease. Clin Chim Açta 115: 55-61, (1981).
• Jain R, Kutty KM, Huang SN: Pseudocholinesteıase; High densty lipoprotein cholesteıol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 29: 1301-1033, (1983).
• Ragaobirsingh D, Bharaj BS. Morrison RY: Change in serum cholinesterase activity in Jamaican diabetics. J Natl Med Assoc 84: 853-855,(1992).
• Friedewald WT, Levy RI. Fıedrickson DS: Estimation of the concentration of low-density lipoprotein cholesteıol in plasma, without use of the preparative ultıacentrifuge. Clin Chem 18: 499- 502, (1972).
• Goldberg RB: Lipid disorders in diabetes. Diabetes Çare 4: 561- 572, (1981).
• Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595-607,(1988).
• Reaven GM, Greenfıeld MS: Diabetic hipertriglyceridemia. Evidence for three clinical syndromes. Diabetes 30: 66-75, (1981).
• Reaven GM, Mondon CE : Effect of in vivo plasma insulin levels on the relationship between perfuse free fatty acid concentration and triglyceride secretion by perfused rat livers. Horm Metab Rev 16: 230-1 107, (1984).
• Kannel WB: Lipids, diabetes and coronary heart disease: Insights from the Framingham study. Am Heart J 110: 1100- 1107,(1985).
• Kissebah AH, Alfarsi S, Evans DJ, Adams PW: Plasma low densty lipoprotein transport kinetics in noninsülin dependent diabetes mellitus. J Clin Invest 171: 655-667, (1983).
• Joıen J, Vielle E: Serum levels of lipoprotein (a) in patients with well controlled noninsulin-dependent diabetes mellitus. J Am Med Assoc 265: 1113-1114,(1991).
• Ören A, Değer O, Karaman SC, Yıldırmış S, Yazıcıoglu Y: Lipoprotein (a) levels in patients with diabetes mellitus. Türk J Med Sci 25: 251-255, (1995).
• Pyola K, Laakso M, Uusitupa M: Diabetes and atherosclerosis : an epidemiologic review. Diabetes Metab Rev 3: 463-524, (1987).
• Velho G, Eılich D, Tupin E, Neel D. Chen D, Froguel P, Pasa P: Lipoprotein (a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Çare 742- 747, (1993).
• Uterman G, Menzel HJ, Kraft HG, Duba HC, Kemmier HG, Seitz CJ: Lp (a) glycoprotein phenotypes. Inheritance and relation to Lp (a)- lipoprotein concentıations in plasma. Clin Invest 80:458- 465,(1987).
• Austin MA, Sandholzer C, Selby JV. Newman B. Krauss RM, Uterman G: Lipoprotein (a) in women twins : heritability and relationship to apolipoprotein (a) phenotypes. Am J Hum Genet 51: 829-840. (1992).
• Özer EM, Akın V, Kutlu H: Tip II diabetes mellitusta metabolik kontrol ile Lp(a) seviyelerinin ilişkisi. Türk Diabet Yıllığı 11: 185-188, (1996).
• Stein EA, Myers GL: Lipids, lipoproteins, and apolipoproteins. In: Burtis CA Ashwood ER, eds. Tietz Textbook of Clinical Chemistry: Philadelphia: WB Sounders 1002-1093, (1994).
• Kutty KM, Redheendıan R, Murphy D: Serum cholinesterase function in lipoprotein metabolism. Experientia 33: 420-423, (1977).
• Kutty KM, Jacop JC: Serum Cholinesterase activity in hiperlipidemia and the in vitıo effect of isoniazid on serum cholinesterase. Canadian of Biochemistry 50: 32-34, (1972)